This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:Evaluate the efficacy of BMS-986489 vs durvalumabEvaluate the safety profile of BMS-986489Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials OfficeEmail: iutrials@iu.eduPhone: (317) 278-5632

The purpose of this study is to investigate the effect of balcinrenone/dapagliflozin compared with dapagliflozin, on the risk of CV death, HF event with and without hospitalization, in patients with chronic HF, impaired kidney function, and who have had a recent HF event.THIS STUDY IS ENROLLING BY INVITATION ONLY

Researchers as the Indiana University Simon Comprehensive Cancer Center are conducting a study to research the safety and effectiveness of increasing doses of CD4CAR T cell therapy for patients who have been diagnosed with, or are being treated for, relapsed or refractory (has not responded to treatment) CD4+ chronic myelomonocytic leukemia (CMML).  CD4+ CMML is a blood cancer that affects white blood cells that express the protein CD4. The CD4CAR therapy is designed to bind to and eliminate cells, including cancer cells that have this protein.  We will evaluate up to 5 different dose levels of CD4CAR T cells and study what side effects occur with these dose levels.  We will also evaluate how effective the dose levels are at treating cancer in the participants in this study.  This therapy is considered investigational which means it has not been approved by the Food and Drug Administration (FDA) as treatment for your.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to find out if a short-term treatment (called a brief intervention) can help youth who screen positive for alcohol and/or substance use reduce their use of substances.  AIM 1:Compare the effectiveness of a youth-focused brief-intervention (TI) when delivered without caregiver involvement (TI-A) vs. with an added caregiver session (TI-A+P) vs. with an online caregiver component (TI-A+FCU) in reducing alcohol use in adolescents with mild AUD in primary care.AIM 2: Identify youth and family factors associated with intervention response vs. non-response in each treatment condition, such as baseline substance use intensity (frequency, volume, duration, type), youth and caregiver perception of alcohol/substance use risk, youth personality factors (impulsivity, emotion dysregulation), and baseline parenting practices. THIS STUDY IS ENROLLING BY INVITATION ONLY - Initial contact with the eligible patients will occur within an IU Health Clinic that is participating within the Integrated Behavioral Health Program. This program employs interventionalists who receive referrals from providers for various mental health and substance abuse concerns. This Interventionalist will ascertain eligibility and provide the patients information about the research study during their visit to clinic. The study team will then contact the eligible patients via phone to answer questions. Upon consent, study participants will be contacted via email and/or phone call.